Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2022

Open Access 01-03-2022 | Retinal Detachment | Original Article – Cancer Research

Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma

Authors: Shiva Sabazade, Viktor Gill, Christina Herrspiegel, Gustav Stålhammar

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2022

Login to get access

Abstract

Purpose

Fluid-conducting extracellular matrix patterns known as vasculogenic mimicry (VM) have been associated with poor prognosis in uveal melanoma and other cancers. We investigate the correlations between VM, presenting symptoms, mortality, and the area density of periodic acid-Schiff positive histological patterns (PAS density).

Methods

Sixty-nine patients that underwent enucleation for uveal melanoma between 2000 and 2007 were included. Clinicopathological parameters presenting symptoms and outcomes were collected. Histological tumor sections were evaluated for VM and PAS density was quantified with digital image analysis.

Results

Thirty-four patients (49%) presented with blurred vision. 18 (26%) with a shadow in the visual field, 7 (10%) with photopsia and/or floaters, and 2 (3%) with metamorphopsia. Nine patients (13%) had no symptoms at all. Median follow-up was 16.7 years (SD 2.6). A shadow in the visual field, but no other symptom, was positively correlated with the presence of VM (φ 0.70, p < 0.001) and greater PAS density (p < 0.001). In multivariate regression, retinal detachment (RD), presence of VM, and PAS density ≥ median were independent predictors of a shadow, but not tumor distance to the macula, tumor apical thickness, tumor diameter, or ciliary body engagement. The presence of VM was associated with significantly shorter cumulative disease-specific survival (Wilcoxon p = 0.04), but not PAS density ≥ median, presenting symptoms or RD (p > 0.28).

Conclusion

Tumors from uveal melanoma patients that report a visual field shadow are likely to display VM and greater PAS density, likely explaining the previously reported association between this symptom and poor prognosis.
Literature
go back to reference Asnaghi L, Lin MH, Lim KS, Lim KJ, Bar EE, Eberhart CG (2013) Targeting the hypoxia pathway in uveal melanoma cells. Acta Ophthalmol 91:0CrossRef Asnaghi L, Lin MH, Lim KS, Lim KJ, Bar EE, Eberhart CG (2013) Targeting the hypoxia pathway in uveal melanoma cells. Acta Ophthalmol 91:0CrossRef
go back to reference Bankhead P, Loughrey M, Fernández J, Dombrowski Y, McArt D, Dunne P, McQuaid S, Gray R, Murray L, Coleman H, James J, Salto-Tellez M, Hamilton P (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878–16878CrossRef Bankhead P, Loughrey M, Fernández J, Dombrowski Y, McArt D, Dunne P, McQuaid S, Gray R, Murray L, Coleman H, James J, Salto-Tellez M, Hamilton P (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878–16878CrossRef
go back to reference Barbagallo C, Caltabiano R, Broggi G, Russo A, Puzzo L, Avitabile T, Longo A, Reibaldi M, Barbagallo D, Di Pietro C, Purrello M, Ragusa M (2020) LncRNA LINC00518 acts as an oncogene in uveal melanoma by regulating an RNA-based network. Cancers 12:3867CrossRef Barbagallo C, Caltabiano R, Broggi G, Russo A, Puzzo L, Avitabile T, Longo A, Reibaldi M, Barbagallo D, Di Pietro C, Purrello M, Ragusa M (2020) LncRNA LINC00518 acts as an oncogene in uveal melanoma by regulating an RNA-based network. Cancers 12:3867CrossRef
go back to reference Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr (2007) Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 21:752–759CrossRef Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr (2007) Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 21:752–759CrossRef
go back to reference Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49:3914–3923CrossRef Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q (2013) Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 49:3914–3923CrossRef
go back to reference Cerri PS, Sasso-Cerri E (2003) Staining methods applied to glycol methacrylate embedded tissue sections. Micron 34:365–372CrossRef Cerri PS, Sasso-Cerri E (2003) Staining methods applied to glycol methacrylate embedded tissue sections. Micron 34:365–372CrossRef
go back to reference COMS (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol 124:1684–1693CrossRef COMS (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol 124:1684–1693CrossRef
go back to reference Damato BE, Coupland SE (2012) Differences in uveal melanomas between men and women from the British Isles. Eye 26:292–299CrossRef Damato BE, Coupland SE (2012) Differences in uveal melanomas between men and women from the British Isles. Eye 26:292–299CrossRef
go back to reference Damato EM, Damato BE (2012) Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology 119:1582–1589CrossRef Damato EM, Damato BE (2012) Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology 119:1582–1589CrossRef
go back to reference Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW (2016) Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol 134:728–733CrossRef Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW (2016) Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol 134:728–733CrossRef
go back to reference Folberg R, Pe’Er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC, Montague PR, Moninger TO, Yi H, Moore KC (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 23:1298–1305CrossRef Folberg R, Pe’Er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H, Moore KC, Montague PR, Moninger TO, Yi H, Moore KC (1992) The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 23:1298–1305CrossRef
go back to reference Folberg R, Fleck M, Mehaffey MG, Meyer M, Bentler SE, Woolson RF, Pe’er J (1996) Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas. Pathol Oncol Res 2:229–236CrossRef Folberg R, Fleck M, Mehaffey MG, Meyer M, Bentler SE, Woolson RF, Pe’er J (1996) Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas. Pathol Oncol Res 2:229–236CrossRef
go back to reference Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S (1996) Microvessel count predicts survival in uveal melanoma. Can Res 56:2900 Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S (1996) Microvessel count predicts survival in uveal melanoma. Can Res 56:2900
go back to reference Foss AJ, Whelehan I, Hungerford JL, Anderson DF, Errington RD, Kacperek A, Restori M, Kongerud J, Sheen M (1997a) Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 81:748–754CrossRef Foss AJ, Whelehan I, Hungerford JL, Anderson DF, Errington RD, Kacperek A, Restori M, Kongerud J, Sheen M (1997a) Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 81:748–754CrossRef
go back to reference Foss AJE, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S (1997b) Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 81:240CrossRef Foss AJE, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S (1997b) Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 81:240CrossRef
go back to reference Fu DA, Campbell-Thompson M (2017) Periodic acid-Schiff staining with diastase. Methods Mol Biol 1639:145–149CrossRef Fu DA, Campbell-Thompson M (2017) Periodic acid-Schiff staining with diastase. Methods Mol Biol 1639:145–149CrossRef
go back to reference Garg G, Finger PT, Kivela TT, Simpson ER, Gallie BL, Saakyan S, Amiryan AG, Valskiy V, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Catala-Mora J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusoz M, Luyten GPM, Singh AD, Suzuki S, AOOT Force (2021) Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-317949CrossRefPubMed Garg G, Finger PT, Kivela TT, Simpson ER, Gallie BL, Saakyan S, Amiryan AG, Valskiy V, Chin KJ, Semenova E, Seregard S, Fili M, Wilson M, Haik B, Caminal JM, Catala-Mora J, Gutierrez C, Pelayes DE, Folgar AM, Jager MJ, Dogrusoz M, Luyten GPM, Singh AD, Suzuki S, AOOT Force (2021) Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol. https://​doi.​org/​10.​1136/​bjophthalmol-2020-317949CrossRefPubMed
go back to reference Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413CrossRef Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413CrossRef
go back to reference Herrspiegel C, Kvanta A, Lardner E, Ramskold Cabaca L, Wells J, Bartuma K, Seregard S, Stalhammar G (2021) Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma. Br J Ophthalmol 105:582–586CrossRef Herrspiegel C, Kvanta A, Lardner E, Ramskold Cabaca L, Wells J, Bartuma K, Seregard S, Stalhammar G (2021) Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma. Br J Ophthalmol 105:582–586CrossRef
go back to reference Karlsson J, Nilsson LM, Mitra S, Alsen S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindner P, Larsson E, Olofsson Bagge R, Nilsson JA (2020) Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun 11:1894CrossRef Karlsson J, Nilsson LM, Mitra S, Alsen S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindner P, Larsson E, Olofsson Bagge R, Nilsson JA (2020) Molecular profiling of driver events in metastatic uveal melanoma. Nat Commun 11:1894CrossRef
go back to reference Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivela TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM (2019) Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 30:1370–1380CrossRef Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivela TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM (2019) Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 30:1370–1380CrossRef
go back to reference Kivela T, Eskelin S, Makitie T, Summanen P (2001) Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol vis Sci 42:2085–2093PubMed Kivela T, Eskelin S, Makitie T, Summanen P (2001) Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol vis Sci 42:2085–2093PubMed
go back to reference Kivelä T, Mäkitie T, Rana’a T, Toivonen P (2004) Microvascular loops and networks in uveal melanoma. Can J Ophthalmol 39:409–421CrossRef Kivelä T, Mäkitie T, Rana’a T, Toivonen P (2004) Microvascular loops and networks in uveal melanoma. Can J Ophthalmol 39:409–421CrossRef
go back to reference Kujala E, Mäkitie T, Kivelä T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol vis Sci 44:4651–4659CrossRef Kujala E, Mäkitie T, Kivelä T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol vis Sci 44:4651–4659CrossRef
go back to reference Mäkitie T, Summanen P, Tarkkanen A, Kivelä T (1999) Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol vis Sci 40:2471PubMed Mäkitie T, Summanen P, Tarkkanen A, Kivelä T (1999) Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol vis Sci 40:2471PubMed
go back to reference Makitie T, Summanen P, Tarkkanen A, Kivela T (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91:359–367CrossRef Makitie T, Summanen P, Tarkkanen A, Kivela T (1999) Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91:359–367CrossRef
go back to reference McLean IW, Keefe KS, Burnier MN (1997) Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 104:777–780CrossRef McLean IW, Keefe KS, Burnier MN (1997) Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 104:777–780CrossRef
go back to reference Meersseman W, Verschueren P, Tousseyn T, De Vos R, Cassiman D (2011) PAS-positive macrophages—not always infection. Lancet 377:1890CrossRef Meersseman W, Verschueren P, Tousseyn T, De Vos R, Cassiman D (2011) PAS-positive macrophages—not always infection. Lancet 377:1890CrossRef
go back to reference Nowak MA, Fatteh SM, Campbell TE (1998) Glycogen-rich malignant melanomas and glycogen-rich balloon cell malignant melanomas: frequency and pattern of PAS positivity in primary and metastatic melanomas. Arch Pathol Lab Med 122:353–360PubMed Nowak MA, Fatteh SM, Campbell TE (1998) Glycogen-rich malignant melanomas and glycogen-rich balloon cell malignant melanomas: frequency and pattern of PAS positivity in primary and metastatic melanomas. Arch Pathol Lab Med 122:353–360PubMed
go back to reference Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW (2012) Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119:1596–1603CrossRef Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM, Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P, Simpson ER, Smith ME, Wilson DJ, Wirostko WJ, Harbour JW (2012) Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119:1596–1603CrossRef
go back to reference Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773 (discussion 774)CrossRef Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773 (discussion 774)CrossRef
go back to reference Rantala ES, Hernberg M, Kivela TT (2019) Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 29:561–568CrossRef Rantala ES, Hernberg M, Kivela TT (2019) Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 29:561–568CrossRef
go back to reference Russo D, Di Crescenzo RM, Broggi G, Merolla F, Martino F, Varricchio S, Ilardi G, Borzillo A, Carandente R, Pignatiello S, Mascolo M, Caltabiano R, Staibano S (2020) Expression of P16INK4a in uveal melanoma: new perspectives. Front Oncol 10:562074CrossRef Russo D, Di Crescenzo RM, Broggi G, Merolla F, Martino F, Varricchio S, Ilardi G, Borzillo A, Carandente R, Pignatiello S, Mascolo M, Caltabiano R, Staibano S (2020) Expression of P16INK4a in uveal melanoma: new perspectives. Front Oncol 10:562074CrossRef
go back to reference See TRO, Stålhammar G, Phillips SS, Grossniklaus HE (2019) BAP1 immunoreactivity correlates with gene expression class in uveal melanoma. Ocul Oncol Pathol 6:1–9 See TRO, Stålhammar G, Phillips SS, Grossniklaus HE (2019) BAP1 immunoreactivity correlates with gene expression class in uveal melanoma. Ocul Oncol Pathol 6:1–9
go back to reference Singh AD (2001) Uveal melanoma: implications of tumor doubling time. Ophthalmology 108:829–830CrossRef Singh AD (2001) Uveal melanoma: implications of tumor doubling time. Ophthalmology 108:829–830CrossRef
go back to reference Stålhammar G, See TRO, Phillips SS, Grossniklaus HE (2019) Density of PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration, and risk for metastasis. Mol vis 25:502–516PubMedPubMedCentral Stålhammar G, See TRO, Phillips SS, Grossniklaus HE (2019) Density of PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration, and risk for metastasis. Mol vis 25:502–516PubMedPubMedCentral
go back to reference Stalhammar G (2020) Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep 10:11297CrossRef Stalhammar G (2020) Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep 10:11297CrossRef
go back to reference Toivonen P, Makitie T, Kujala E, Kivela T (2003) Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res 27:237–245CrossRef Toivonen P, Makitie T, Kujala E, Kivela T (2003) Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res 27:237–245CrossRef
go back to reference Uner OE, See TRO, Szalai E, Grossniklaus HE, Stalhammar G (2021) Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep 11:8923CrossRef Uner OE, See TRO, Szalai E, Grossniklaus HE, Stalhammar G (2021) Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep 11:8923CrossRef
Metadata
Title
Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma
Authors
Shiva Sabazade
Viktor Gill
Christina Herrspiegel
Gustav Stålhammar
Publication date
01-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2022
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03851-9

Other articles of this Issue 3/2022

Journal of Cancer Research and Clinical Oncology 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine